about
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptidesThe ring residue proline 8 is crucial for the thermal stability of the lasso peptide caulosegnin IIExploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) AntagonistsMechanistic insight into ligand binding to G-quadruplex DNAMarine and semi-synthetic hydroxysteroids as new scaffolds for pregnane X receptor modulationBasic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands.Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.Discovery of N-aryl-naphthylamines as in vitro inhibitors of the interaction between HIV integrase and the cofactor LEDGF/p75.Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists.Protein flexibility in virtual screening: the BACE-1 case studyPhenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors.Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases.State-of-the-art methodologies for the discovery and characterization of DNA G-quadruplex binders.Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands.Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives.Exploring the chemical space of G-quadruplex binders: discovery of a novel chemotype targeting the human telomeric sequence.New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism.Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.Monothiocarbamates Strongly Inhibit Carbonic Anhydrases in Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma.Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.From a Helix to a Small Cycle: Metadynamics-Inspired αvβ6 Integrin Selective Ligands.Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells.Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimizationEpoxide functionalization on cholane side chains in the identification of G-protein coupled bile acid receptor (GPBAR1) selective agonistsIntroduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic PropertiesStructural Insight into the Binding Mode of FXR and GPBAR1 ModulatorsNovel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver InjuryInvestigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists
P50
Q27690775-CF4C3152-1A60-4859-AABC-BB009EFB3FB3Q27703999-5C921149-6FA8-4AD1-8666-3A994B1CB874Q27727757-D981AA4F-55EB-454D-8549-A9B8A9F9759BQ33635614-50BE5A2C-A20D-4183-B735-AE9EBF51D3DDQ33808887-95153CAA-A33E-48AF-85F5-EAA25B3200CBQ34372481-DFD301A3-5813-48D5-A8FD-865278F44492Q34567390-3A897F5C-A978-4852-9884-62C1DDF7C317Q34710678-636C5ECE-0528-49FB-90AC-F02603EDA718Q35127140-599EF207-A3D6-4A80-A799-242B559386CBQ35684884-D46B94AD-7F2C-46C9-AE28-77BCBF2EF533Q36289268-74AF4C2D-E52D-43E8-9D74-29ECC90708C7Q36470957-589AD0BC-9466-46C0-8960-FF1DAD34449EQ37695391-DF9563AF-A1D8-4197-9FC6-F86107991384Q37727582-CCBB1119-6C0D-409A-BF8C-6CD9651F4CE1Q37989213-BC2DBBD5-4344-4DC2-AD4C-5633D42FFFB2Q38705998-1F951FE8-0D23-46B1-B866-4E267B3823B5Q38811936-F8516FC7-5A0F-4896-BBF2-101DA8358347Q38968700-6EF232D5-D7E1-41A8-AFC6-B05AFDEAFDFCQ39060815-A0C792D9-8EB5-4913-A53F-786D92806DA0Q39360609-C8DC81DD-BE2E-4EB8-88F9-215455717CECQ41242092-7C13C35A-EAA4-479D-BCEA-C08CE1630B6BQ43175647-B2810CBE-30A8-463F-8580-1FD638F74531Q47417227-72B2F8E6-324A-404A-ADF5-1A1E10A9AE0DQ47600958-3F510F21-806A-4DEE-B6E6-D84B38D05387Q51724263-D37CD9C1-E7D2-47C3-969E-48C5FA4EB04BQ51761413-DA52493F-FFC3-4487-923B-F01BE8565156Q52585344-989DD8E1-E9AF-4249-B9F0-98C7D88504FEQ52664347-C6A1AF65-00FE-455A-B398-C0A211BB92F2Q57149907-511A3C94-346E-4378-B05F-48AFDEB8186DQ58308143-DEE7A729-74D2-4951-AD5D-E6F3FA87B1BFQ58861672-46CD26C4-593F-49DB-9686-BE46FAB83D58Q64084645-6A7936EB-5FF7-436D-A923-9AA43B6B58D0Q92505774-1AB53697-611C-4D85-A832-09DCE0FF02D6Q93166573-4EA422DA-E2C0-460D-A4C7-112D8B4664DAQ93166677-1A4700A8-165D-4D29-B8AE-320E8084C2EF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Saverio Di Leva
@ast
Francesco Saverio Di Leva
@en
Francesco Saverio Di Leva
@es
Francesco Saverio Di Leva
@nl
Francesco Saverio Di Leva
@sl
type
label
Francesco Saverio Di Leva
@ast
Francesco Saverio Di Leva
@en
Francesco Saverio Di Leva
@es
Francesco Saverio Di Leva
@nl
Francesco Saverio Di Leva
@sl
prefLabel
Francesco Saverio Di Leva
@ast
Francesco Saverio Di Leva
@en
Francesco Saverio Di Leva
@es
Francesco Saverio Di Leva
@nl
Francesco Saverio Di Leva
@sl
P106
P1153
54385049800
P21
P31
P496
0000-0002-2294-0656